CRISPR Therapeutics (CRSP) News
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRSP news summary
We found 6 recent headlines mentioning CRISPR Therapeutics (CRSP): 4 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. CRSP is making an outsized move today, up 5.85% at $53.39, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest CRISPR Therapeutics headlines
- Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.NasdaqCRSP, VRTX
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Studyargenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.NasdaqARGX, ALNY, CRSP
- AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.NasdaqABBV, BMY, CRSP, ACTU
- CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ® , its investigational…GlobeNewswire
- CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?Key PointsCRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY.NasdaqCRSP, VRTX
- Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?Key PointsCRISPR Therapeutics will likely be a much larger company in 10 years.NasdaqCRSP, NVS, VRTX